BRPI0513549A - composições farmacêuticas para o tratamento de leishmaniose - Google Patents

composições farmacêuticas para o tratamento de leishmaniose

Info

Publication number
BRPI0513549A
BRPI0513549A BRPI0513549-4A BRPI0513549A BRPI0513549A BR PI0513549 A BRPI0513549 A BR PI0513549A BR PI0513549 A BRPI0513549 A BR PI0513549A BR PI0513549 A BRPI0513549 A BR PI0513549A
Authority
BR
Brazil
Prior art keywords
treatment
leishmaniasis
pharmaceutical compositions
parasitic diseases
precursors
Prior art date
Application number
BRPI0513549-4A
Other languages
English (en)
Inventor
Ali Ouaissi
Denis Sereno
Baptiste Vergens
Original Assignee
Inst Rech Pour Le Developpment
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Rech Pour Le Developpment filed Critical Inst Rech Pour Le Developpment
Publication of BRPI0513549A publication Critical patent/BRPI0513549A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçõES FARMACêUTICAS PARA O TRATAMENTO DE LEISHMANIOSE. A presente invenção se refere ao uso de pelo menos um composto da seguinte fórmula geral (I): no qual R representa OH ou NH~ 2~, ou de precursores ou derivados deste, ou dos sais farmaceuticamente aceitáveis de referido composto ou de seus precursores ou derivados, para a manufatura de um medicamento pretendido para a prevenção ou tratamento de doenças parasíticas, em particular de doenças parasíticas de protozoário, mais particularmente de leishmaniose, e especialmente para a prevenção ou para o tratamento de doenças parasíticas que ocorrem em pacientes imunodepressivos.
BRPI0513549-4A 2004-07-19 2005-07-15 composições farmacêuticas para o tratamento de leishmaniose BRPI0513549A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58880204P 2004-07-19 2004-07-19
PCT/EP2005/007715 WO2006008082A1 (en) 2004-07-19 2005-07-15 Pharmaceutical compositions for the treatment of leishmaniasis

Publications (1)

Publication Number Publication Date
BRPI0513549A true BRPI0513549A (pt) 2008-05-06

Family

ID=34979717

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513549-4A BRPI0513549A (pt) 2004-07-19 2005-07-15 composições farmacêuticas para o tratamento de leishmaniose

Country Status (7)

Country Link
US (1) US20080039430A1 (pt)
EP (1) EP1768669B1 (pt)
AT (1) ATE447953T1 (pt)
BR (1) BRPI0513549A (pt)
DE (1) DE602005017629D1 (pt)
ES (1) ES2333889T3 (pt)
WO (1) WO2006008082A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010054382A1 (en) * 2008-11-10 2010-05-14 Elixir Pharmaceuticals, Inc. Compounds, compositions, and methods for treating malaria or leishmaniasis
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302459A (en) * 1980-03-19 1981-11-24 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in leishmaniasis chemotherapy with 8-aminoquinoline derivatives
US4399151A (en) * 1980-06-16 1983-08-16 Merrell Dow Pharmaceuticals Inc. Method of inhibiting the growth of protozoa
DE3269389D1 (en) * 1981-08-10 1986-04-03 Wellcome Found Pharmaceutical formulations containing antimony
GB8330969D0 (en) * 1983-11-21 1983-12-29 Wellcome Found Promoting healing
PT802257E (pt) * 1996-04-19 2003-01-31 Nestle Sa Linhagem imortalizada de celulas epiteliais do colon humano
JP2001515916A (ja) * 1997-09-11 2001-09-25 オクシジェン，インコーポレイテッド 悪性および伝染性疾患の治療用にニコチンアミド・アデニン・ジヌクレオチドならびにその類似物を用いる治療法
US6207879B1 (en) * 1999-05-14 2001-03-27 Dekalb Genetics Corporation Maize RS81 promoter and methods for use thereof
AU4961600A (en) * 1999-06-20 2001-01-09 Elnour Abdel Magid Osman Potentiation of chloroquine

Also Published As

Publication number Publication date
WO2006008082A1 (en) 2006-01-26
EP1768669A1 (en) 2007-04-04
ATE447953T1 (de) 2009-11-15
EP1768669B1 (en) 2009-11-11
ES2333889T3 (es) 2010-03-02
US20080039430A1 (en) 2008-02-14
DE602005017629D1 (de) 2009-12-24

Similar Documents

Publication Publication Date Title
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
SE0202462D0 (sv) Novel use
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
GB0112348D0 (en) Compounds
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
SE0202429D0 (sv) Novel Compounds
EP2620145A3 (en) 2,5-dihydroxybenzene compounds for the treatment of of cancer of an organ
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
UA83233C2 (ru) Замещенный 2-аминотетралин для лечения депрессии
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
DK1641454T3 (da) Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
SE9901573D0 (sv) New compounds
WO2006116733A3 (en) Protein kinase inhibitors
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
WO2006051314A3 (en) Guanidine derivatives as inhibitors of ddah
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
BRPI0513549A (pt) composições farmacêuticas para o tratamento de leishmaniose
SE9901572D0 (sv) New compounds
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
WO2006031719A3 (en) 1,4-bis-n-oxide-5,8-dihydroxyanthracenedione compounds and the use thereof

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2315 DE 19-05-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.